Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
GRAL · against 218 other Healthcare companies of similar size
Ranked #174 of 219 · scores higher than 1% of peers
Bars: peers in each 10-point band of the valuation score46 peers with a valuation score of 0–9, including GRAL · Click a bar to see the companies
Mainly because of its EBITDA yield, earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | GRAL | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 216 reported | -7.0% | 2.6% | 7% | 30% | |
| EBITDA yieldHigher is better · 217 reported | -6.9% | 4.8% | 6% | 50% | |
| Free cash flow yieldHigher is better · 124 reported | -4.8% | 1.2% | 14% | 20% | |
| Book yieldHigher is better · 217 reported | 40.8% | 25.9% | 74% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 37.3B HKD (≈$4.8B) | 99 | 90 | |
| 3 | 89.5B HKD (≈$11.5B) | 98 | 67 | |
| 4 | 10.4B USD | 96 | 64 | |
| 5 | 80.2B CNY (≈$11.2B) | 95 | 76 | |
| 174 | 3.4B USD | 8 | 35 | |
| 174 | 3.3B USD | 8 | 44 | |
| 174 | 5.1B USD | 8 | 35 | |
| 174 | 4.1B USD | 8 | 42 | |
| 174 | 6.2B USD | 8 | 44 | |
| 174 | 6.0B USD | 8 | 30 | |
| 174 | 4.7B USD | 8 | 46 | |
| 174 | 8.8B USD | 8 | 31 | |
| 174 | 6.0B USD | 8 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score